<?xml version="1.0" encoding="utf-8" ?>
<feed xmlns="http://www.w3.org/2005/Atom">
<title>Rhiduvaxer - Latest News</title>
<link href="https://news.arcnewswire.com/rss/rhiduvaxer/latest.xml"></link>
<updated>2026-09-20T02:33:13+00:00</updated>
<id>urn:uuid:2fa40eed-cc7b-90e4-b6ca-448322d101a6</id>
<entry>
<title>cope with this in a 2nd. But first, allow’s speak</title>
<link href="https://news.arcnewswire.com/@rhiduvaxer/cope-with-this-in-a-2nd-but-first-allow-s-speak-aw34xqwnn354"></link>
<id>urn:uuid:a516a8d8-64fd-8e05-fd95-d503027d3229</id>
<summary type="html"><![CDATA[Effectiveness and side outcomes apart, will you pay loads for TST 1700? We’ll cope with this in a 2nd. But first, allow’s speak]]></summary>
<updated>2017-03-04T06:03:34+00:00</updated>
</entry>
</feed>